Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category (Ascending) Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
00078-0627-51 00078-0627 Everolimus Afinitor 3.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Aug. 29, 2012 In Use
00078-0627-61 00078-0627 Everolimus Afinitor 3.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Aug. 29, 2012 In Use
00078-0628-51 00078-0628 Everolimus Afinitor 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Aug. 29, 2012 In Use
00078-0628-61 00078-0628 Everolimus Afinitor 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Aug. 29, 2012 In Use
00078-0670-66 00078-0670 Pazopanib Hydrochloride Votrient 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, KIT, Lck, FMS Oral July 12, 2016 Oct. 31, 2024 In Use
00078-0698-02 00078-0698 RYDAPT Rydapt 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FLT3 Oral April 28, 2017 In Use
00078-0698-19 00078-0698 RYDAPT Rydapt 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FLT3 Oral April 28, 2017 In Use
00078-0698-51 00078-0698 RYDAPT Rydapt 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FLT3 Oral April 28, 2017 In Use
00078-0698-99 00078-0698 RYDAPT Rydapt 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FLT3 Oral April 28, 2017 In Use
00078-0709-56 00078-0709 Capmatinib TABRECTA 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor MET Oral May 6, 2020 In Use
00078-0709-94 00078-0709 Capmatinib TABRECTA 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor MET Oral May 6, 2020 In Use
00078-0716-56 00078-0716 Capmatinib TABRECTA 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor MET Oral May 6, 2020 In Use
00078-0716-94 00078-0716 Capmatinib TABRECTA 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor MET Oral May 6, 2020 In Use
00078-0867-14 00078-0867 Ribociclib Kisqali 200.0 mg/1, 200.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral March 13, 2017 In Use
00078-0867-42 00078-0867 Ribociclib Kisqali 200.0 mg/1, 200.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral March 13, 2017 In Use
00078-0874-21 00078-0874 Ribociclib Kisqali 200.0 mg/1, 200.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral March 13, 2017 In Use
00078-0874-63 00078-0874 Ribociclib Kisqali 200.0 mg/1, 200.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral March 13, 2017 In Use
00085-1366-01 00085-1366 Temozolomide Temodar 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 11, 1999 May 29, 2015 In Use
00085-1366-02 00085-1366 Temozolomide Temodar 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 11, 1999 May 29, 2015 In Use
00085-1366-03 00085-1366 Temozolomide Temodar 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 11, 1999 In Use
00085-1366-04 00085-1366 Temozolomide Temodar 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 11, 1999 In Use
00085-1366-05 00085-1366 Temozolomide Temodar 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Nov. 2, 2012 In Use
00085-1417-01 00085-1417 Temozolomide Temodar 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 11, 1999 Oct. 22, 2014 In Use
00085-1417-02 00085-1417 Temozolomide Temodar 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 11, 1999 In Use
00085-1417-03 00085-1417 Temozolomide Temodar 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Nov. 2, 2012 In Use

Found 10,000 results in 7 milliseconds — Export these results